Novartis’ hopes of catching up with other companies in immuno-oncology have been dented after PD-1 inhibitor spartalizumab failed a phase 3 trial in skin cancer. Novartis had hoped the COMBI-i ...

showing minimal PD-1 expression. Image Credit: ACROBiosystems Human CD4+ cells were activated using GMP ActiveMax Human T Cell Activation/Expansion CD3/CD28 Beads (Cat. No. GMP-MBS001) and ...